Related Experiment Video

Updated: Jul 26, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

H A Lane1, A B Motoyama, I Beuvink

  • 1Friedrich Miescher Institute, Basel, Switzerland. heidi.lane@pharma.novartis.com

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 28, 2001
PubMed

Insights

The anti-HER2 antibody 4D5 halts cancer cell proliferation by disrupting HER2 signaling, leading to p27 protein release and cell cycle arrest. This mechanism explains how anti-HER2 therapies like Herceptin work.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • HER2-overexpressing cancers are driven by elevated HER2 receptor signaling.
  • Monoclonal antibodies targeting HER2, like 4D5, show anti-proliferative effects.
  • Understanding the precise molecular mechanisms is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To investigate the molecular mechanisms behind the anti-proliferative effects of the anti-HER2 antibody 4D5.
  • To elucidate the role of p27 protein and cell cycle regulation in response to 4D5 treatment.
  • To establish a predictive model for response to anti-HER2 therapies.

Main Methods:

  • Treatment of HER2-overexpressing human carcinoma cell lines (BT-474, SKBR3, MKN7) with 4D5 antibody or control antibody (FRP5).
  • Analysis of cell cycle progression (G1 accumulation).
  • Assessment of protein expression and complex formation related to cyclin E/Cdk2 inhibition (p27).
  • Use of antisense technology to evaluate the role of increased p27 expression.

Main Results:

  • 4D5 induced G1 cell cycle arrest in BT-474 and SKBR3 cells.
  • This arrest was associated with reduced expression of p27 sequestration proteins, increased p27-Cdk2 complex formation, and Cdk2 inactivation.
  • Increased p27 expression was observed but not essential for the G1 block.
  • MKN7 cells, insensitive to 4D5, did not exhibit these molecular changes.

Conclusions:

  • 4D5 antibody disrupts HER2 signaling, leading to p27 release and inhibition of cyclin E/Cdk2, thus blocking G1/S phase progression.
  • The findings suggest that tumor cell dependency on HER2 signaling for p27 sequestration proteins dictates response to anti-HER2 therapy.
  • This provides a molecular basis for the efficacy of Herceptin (trastuzumab) in HER2-positive cancers.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...